<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114249">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01814267</url>
  </required_header>
  <id_info>
    <org_study_id>DCIC 12 07</org_study_id>
    <nct_id>NCT01814267</nct_id>
  </id_info>
  <brief_title>Medico-economical Assessment of Telemedicine During Chronic Diabetes-related Foot Wound Management</brief_title>
  <acronym>AIRPEDIA</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the cost-effectiveness of telemedicine in the care of
      chronic diabetic foot ulcers.

      Patients will be randomized into 2 groups: 1/conventional care group with iterative visits
      to diabetes specialist or 2/innovative care (telemedicine group).

      the health insurance system perspective is adopted.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Assess the incremental cost-effectiveness ratio from the french health  system perspective</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>It is elaborated from:
Main cost criteria: transport, outpatient costs (home nursing care, physicians consultations...), loss of productivity (absence from work)
Main clinical effectiveness criterion: wound healing time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the Impact of telemedicine care from the hospital perspective</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The incremental cost-effectiveness ratio is calculated from the hospital perspective:
Main cost criteria will be collected according to the micro-costing method: costs of innovative medical device (implementation and maintenance of telemedicine platform), telemedicine physician consultations, standard consumables, cost of care rooms and cost of medical and paramedical staff and, standard consumables for wound treatment.
Costs will not include structural costs
Main clinical effectiveness criterion: wound healing time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess acceptability of telemedicine care (compliance and satisfaction) for patients and nurses.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Acceptability questionnaire for nurse including use or misuse of telemedicine. Acceptability questionnaire for patient.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Telemedicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>care and follow-up through telemedicine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>care and follow-up through iterative diabetes physician consultations (conventional care and follow-up)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>telemedicine</intervention_name>
    <description>Intervention group: care and follow-up through telemedicine (e-consultations)
1 hospital consultation at inclusion time, week 0
then every 15 days, after the transmission of medical data and photos via internet by the nurse, telemedicine e-consultations until the wound has healed (week 2,week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18, week 20, week 22, week 24 : end point study), i.e. 12 e-consultations over a 6-month period.
1 hospital consultation to validate that the wound is well-healed</description>
    <arm_group_label>Telemedicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>conventional</intervention_name>
    <description>conventional group: iterative diabetes physicians consultations at hospital
1 consultation at inclusion time, week 0
1 consultation 2 weeks after inclusion, week 2
1 consultation per month until the wound has healed (week 4, week 8, week 12, week 16, week 20, week 24: end-point study), i.e. 6 consultations over a 6-month period
1 consultation to validate that the wound is well-healed</description>
    <arm_group_label>Conventional care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 1 or 2 diabetes, at least 18 years old

          -  Patient with a diabetic foot wound :

               -  Acute or chronic (evolving for at least 30 days)

               -  size ≤ to 3 cm²

               -  Level I, II or III, stage A or B, excluding stages C and D from the University
                  of Texas Wound Classification Systems

          -  Person affiliated to French Health insurance or equivalent

          -  Person having signed freely the consent form after receiving sufficient information

          -  Treatment compliance and 6 months follow-up feasible

        Exclusion Criteria:

          -  Patient with a ischemic wound: Ankle-Brachial Index (ABI) &lt;0.9 or Transcutaneous
             oxygen pressure (TcpO2) &lt; 30 mmHg (stage C and D from the University of Texas Wound
             Classification Systems)

          -  Patient with emergency hospitalization indication whatever the reasons.

          -  Person deprived of liberty by a legal or administrative decision, patients in
             emergency and people hospitalised without consent and who are not protected by law.

          -  Pregnant or breastfeeding women

          -  Patient currently participating in another telemedicine research protocol (such as :
             Study on the impact of Telemedicine on the management of patients with type 1
             diabetes (TELEDIAB-3))
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Yves BENHAMOU, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra DAVID TCHOUDA, MD PHD</last_name>
    <phone>0033476767186</phone>
    <email>SDavidTchouda@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion PROUST, CRA</last_name>
    <phone>0033476767312</phone>
    <email>MProust@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38049</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Yves BENHAMOU, PU PH</last_name>
      <phone>0033476769349</phone>
      <email>PYBenhamou@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marie MULLER, MD</last_name>
      <phone>0033476765165</phone>
      <email>MMuller@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Marie MULLER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Hazenberg CE, Bus SA, Kottink AI, Bouwmans CA, Schönbach-Spraul AM, van Baal SG. Telemedical home-monitoring of diabetic foot disease using photographic foot imaging--a feasibility study. J Telemed Telecare. 2012 Jan;18(1):32-6. doi: 10.1258/jtt.2011.110504. Epub 2011 Nov 8.</citation>
    <PMID>22067285</PMID>
  </reference>
  <reference>
    <citation>Foltynski P, Ladyzynski P, Migalska-Musial K, Sabalinska S, Ciechanowska A, Wojcicki J. A new imaging and data transmitting device for telemonitoring of diabetic foot syndrome patients. Diabetes Technol Ther. 2011 Aug;13(8):861-7. doi: 10.1089/dia.2011.0004. Epub 2011 May 13.</citation>
    <PMID>21568750</PMID>
  </reference>
  <reference>
    <citation>Bowling FL, King L, Paterson JA, Hu J, Lipsky BA, Matthews DR, Boulton AJ. Remote assessment of diabetic foot ulcers using a novel wound imaging system. Wound Repair Regen. 2011 Jan-Feb;19(1):25-30. doi: 10.1111/j.1524-475X.2010.00645.x. Epub 2010 Dec 6.</citation>
    <PMID>21134035</PMID>
  </reference>
  <reference>
    <citation>Larsen SB, Clemensen J, Ejskjaer N. A feasibility study of UMTS mobile phones for supporting nurses doing home visits to patients with diabetic foot ulcers. J Telemed Telecare. 2006;12(7):358-62.</citation>
    <PMID>17059653</PMID>
  </reference>
  <reference>
    <citation>Wilbright WA, Birke JA, Patout CA, Varnado M, Horswell R. The use of telemedicine in the management of diabetes-related foot ulceration: a pilot study. Adv Skin Wound Care. 2004 Jun;17(5 Pt 1):232-8.</citation>
    <PMID>15192491</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 17, 2013</lastchanged_date>
  <firstreceived_date>March 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Grenoble</investigator_affiliation>
    <investigator_full_name>AdministrateurCIC</investigator_full_name>
    <investigator_title>Pr Pierre-Yves BENHAMOU, University Hospital, Grenoble</investigator_title>
  </responsible_party>
  <keyword>innovative care</keyword>
  <keyword>telemedicine</keyword>
  <keyword>cost effectiveness</keyword>
  <keyword>diabetes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
